Cause-specific death and risk factors of one-year mortality after implantable cardioverter-defibrillator implantation: a nationwide study.

AIMS Current treatment guidelines recommend implantable cardioverter-defibrillators (ICDs) in eligible patients with an estimated survival beyond one year. There is still an unmet need to identify patients who are unlikely to benefit from an ICD.We determined cause-specific one-year mortality after ICD implantation and identified associated risk factors. METHODS AND RESULTS Using Danish nationwide registries (2000-2017), we identified 14,516 patients undergoing first-time ICD implantation for primary or secondary prevention. Risk factors associated with one-year mortality were evaluated using multivariable logistic regression. The median age was 66 years, 81.3% were male, and 50.3% received an ICD for secondary prevention. The one-year mortality rate was 4.8% (694/14,516). ICD recipients who died within one year were older and more comorbid compared to those who survived (72 vs. 66 years, p < 0.001). Risk factors associated with increased one-year mortality included dialysis (OR:3.26, CI:2.37-4.49), chronic renal disease (OR:2.14, CI:1.66-2.76), cancer (OR:1.51, CI:1.15-1.99), age 70-79 years (OR:1.65, CI:1.36-2.01), and age ≥80 years (OR:2.84, CI:2.15-3.77). The one-year mortality rates for the specific risk factors were: dialysis (13.8%), chronic renal disease (13.1%), cancer (8.5%), age 70-79 years (6.9%), and age ≥80 years (11.0%). Overall, the most common causes of mortality were related to cardiovascular diseases (62.5%), cancer (10.1%), and endocrine disorders (5.0%). However, the most common cause of death among patients with cancer was cancer-related (45.7%). CONCLUSION Among ICD recipients, mortality rates were low and could be indicative of relevant patient selection. Important risk factors of increased one-year mortality included dialysis, chronic renal disease, cancer, and advanced age.

[1]  C. Torp‐Pedersen,et al.  Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers , 2020, Clinical epidemiology.

[2]  M. Kamalesh,et al.  One‐year mortality after implantable cardioverter‐defibrillator placement within the Veterans Affairs Health System , 2020, European journal of heart failure.

[3]  E. Marcantonio,et al.  One-Year Mortality After Dialysis Initiation Among Older Adults. , 2019, JAMA internal medicine.

[4]  H. Putter,et al.  Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. , 2019, Circulation.

[5]  G. Gislason,et al.  Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  A. Brandes,et al.  Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure , 2017, Circulation.

[7]  P. Austin,et al.  Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population‐Based Registry , 2017, Journal of the American Heart Association.

[8]  R. Tilz,et al.  Implantable cardioverter defibrillator use for primary prevention in ischaemic and non-ischaemic heart disease—indications in the post-DANISH trial era: results of the European Heart Rhythm Association survey , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  H. Bøtker,et al.  Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study , 2016, BMJ Open.

[10]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[11]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[12]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[13]  H. Bøtker,et al.  Thirteen-year nationwide trends in use of implantable cardioverter-defibrillators and subsequent long-term survival. , 2015, Heart rhythm.

[14]  M. Turakhia,et al.  A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. , 2015, American heart journal.

[15]  Yiyi Zhang,et al.  Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients. , 2015, Heart rhythm.

[16]  P. Kudenchuk,et al.  Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. , 2014, JACC. Heart failure.

[17]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[18]  P. Weeke,et al.  Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  J. Healey,et al.  Survival After Implantable Cardioverter-Defibrillator Implantation in the Elderly , 2013, Circulation.

[20]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[21]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[22]  K. Helweg-larsen The Danish Register of Causes of Death , 2011, Scandinavian journal of public health.

[23]  Vibeke Jensen,et al.  Danish education registers , 2011, Scandinavian journal of public health.

[24]  J. Svendsen,et al.  Nationwide study of sudden cardiac death in persons aged 1-35 years. , 2011, European heart journal.

[25]  Jeroen J. Bax,et al.  Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  M. Link,et al.  Predictors of Early Mortality in Patients Age 80 and Older Receiving Implantable Defibrillators , 2010, Pacing and clinical electrophysiology : PACE.

[27]  K. Stein,et al.  Predictors of early mortality in implantable cardioverter-defibrillator recipients , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  Deepak L. Bhatt,et al.  Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. , 2009, The American journal of cardiology.

[29]  D. Mark,et al.  Prognostic importance of defibrillator shocks in patients with heart failure. , 2008, The New England journal of medicine.

[30]  M. Sweeney,et al.  Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial , 2005, Circulation.

[31]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[32]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[33]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[34]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[35]  A. Baranchuk,et al.  Increased Incidence of Ventricular Arrhythmias in Patients With Advanced Cancer and Implantable Cardioverter-Defibrillators. , 2017, JACC. Clinical electrophysiology.

[36]  L. Jordaens,et al.  Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[37]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[38]  D. Hodge,et al.  Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. , 2012, Heart rhythm.

[39]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death ACC/AHA TASK FORCE MEMBERS ESC COMMITTEE FOR PRACTICE GUIDELINES , 2006 .

[40]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.